19 / 76
HIPERTENSIÓN / 2017 / VOL. 22
19
Referencias
1. Kolkhof P, Bärfacker L. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and
development. J Endocrinol. 2017;234:T125–T140.
2. DuPont JJ, Jaffe IZ. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature. Journal of
Endocrinology. 2017;234:T67–T82.
3. Flatt DM, Brown MC, Mizeracki AM, King BJ, Weber KT. Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant
Hypertension. JAMA Cardiol. 2016;1:607–6.
4. Sica DA. Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure. Methodist Debakey Cardiovasc J. 2015;11:235–239.
5. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K. Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive
Patients. Hypertension. 2002;40:117–123.
6. Weinberger MH, White WB, Ruilope L-M, MacDonald TM, Davidson RC, Roniker B, Patrick JL, Krause SL. Effects of eplerenone versus losartan in
patients with low-renin hypertension. American Heart Journal. 2005;150:426–433.
7. Yugar-Toledo JC, Modolo R, de Faria AP, Moreno H. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. VHRM.
2017;Volume 13:403–411.
8. Maiolino G, Azzolini M, Rossi GP. Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines! Front
Cardiovasc Med. 2015;2.
9. MD ME, PhD DADM. Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016. AJM. 2016;129:661–666.
10. Rosa J, Zelinka T, Petrák O, Štrauch B, Holaj R, Widimský J. Should All Patients with Resistant Hypertension Receive Spironolactone? Curr Hypertens
Rep. 2016;:1–10.
11. Dudenbostel T, Calhoun DA. Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension. American Journal of Hypertension.
2017;30:103–109.
12. Narayan H, Webb DJ. New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension. Curr Hypertens
Rep. 2016;:1–7.
13. Eirin A, Textor SC, Lerman LO. Emerging concepts for patients with treatment-resistant hypertension. Trends in Cardiovascular Medicine. 2016;26:700–706.
14. Di Zhao, Liu H, Dong P, Zhao J. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. International Journal of
Cardiology. 2017;233:113–117.
15. Maron BA, Leopold JA. Aldosterone Receptor Antagonists: Effective but Often Forgotten. Circulation. 2010;121:934–939.
16. Guo H, Xiao Q. Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials. Int J Clin Exp
Med. 2015;8:7270–7278.
17. Wang C, Xiong B, Huang J. Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled
Trials. Heart, Lung and Circulation. 2016;25:1021–1030.
18. Tam TS, Wu MH, Masson SC, Tsang MP, Stabler SN, Kinkade A, Tung A, Tejani AM. Eplerenone for hypertension. Cochrane Database of Systematic
Reviews. 2017;124:1945–50.
19. MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, Ford I, Sever P, Mackenzie IS, Padmanabhan S, McCann GP, Salsbury J,
McInnes G, Brown MJ, British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY).
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. J Am
Heart Assoc. 2017;6:e006986.
20. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury
J, Brown MJ, British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study
Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2
mechanisms substudies. Lancet Diabetes Endocrinol. 2018;
21. Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, Russell RP. The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension:
A Meta-Analysis of Randomized and Nonrandomized Studies. American Journal of Hypertension. 2015;28:1376–1385.
22. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone
and losartan in hypertensive black and white patients. JAC. 2003;41:1148–1155.
23. Williams GH, Burgess E, Kolloch RE, Ruilope L-M, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL. Efficacy of eplerenone versus enalapril
as monotherapy in systemic hypertension. AJC. 2004;93:990–996.
24. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril,
and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation.
2003;108:1831–1838.
25. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the Selective Aldosterone Blocker Eplerenone Versus
the Calcium Antagonist Amlodipine in Systolic Hypertension. Hypertension. 2003;41:1021–1026.
26. Yano Y, Hoshide S, Tamaki N, Nagata M, Sasaki K, Kanemaru Y, Shimada K, Kario K. Efficacy of eplerenone added to renin-angiotensin blockade in
elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study. J Renin Angiotensin Aldosterone Syst. 2010;12:340–347.
27. Calhoun DA. Refractory and Resistant Hypertension: Antihypertensive Treatment Failure versus Treatment Resistance. Korean Circ J. 2016;46:593–8.
28. Calhoun DA. Low-Dose Aldosterone Blockade as a New Treatment Paradigm for Controlling Resistant Hypertension. The Journal of Clinical Hypertension.
2007;9:19–24.
29. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. Journal of the American
Society of Hypertension. 2008;2:462–468.
30. Seferovic PM, Pelliccia F, Zivkovic I, Ristic A, Lalic N, Seferovic J, Simeunovic D, Milinkovic I, Rosano G. Mineralocorticoid receptor antagonists, a class
beyond spironolactone — Focus on the special pharmacologic properties of eplerenone. International Journal of Cardiology. 2015;200:3–7.
31. Pitt B, Rossignol P. The association between serum potassium and mortality in patients with hypertension: 'a wake-up call'. European Heart Journal.
2017;38:113–115.
32. Krogager ML, Torp-Pedersen C, Mortensen RN, Kober L, Gislason G, Søgaard P, Aasbjerg K. Short-term mortality risk of serum potassium levels in
hypertension: a retrospective analysis of nationwide registry data. European Heart Journal. 2017;38:104–112.
33. PITT B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients
with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.
34. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after
myocardial infarction. N Engl J Med. 2003;348:1309–1321.
35. Lazich I, Bakris GL. Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease. YSNEP. 2014;34:333–339.
36. Takahashi S, Hiramatsu M, Hotta S, Watanabe Y, Suga O, Endo Y, Miyamori I. Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from
a Postmarketing Surveillance in Japan. International Journal of Hypertension. 2016;2016:1–9.
37. Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C. Safety profile of mineralocorticoid receptor antagonists:
Spironolactone and eplerenone. International Journal of Cardiology. 2015;200:25–29.
38. Chomicki J, Klem P, Marrs J. Evaluation of the incidence of hyperkalemia in patients prescribed spironolactone for the treatment of resistant hypertension.
Journal of the American Society of Hypertension. 2014;8:e30–e31.
39. Kolkhof P, Jaisser F, Kim S-Y, Filippatos G, Nowack C, Pitt B. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure
and Cardiorenal Diseases: Comparison at Bench and Bedside. In: Heart Failure. Cham: Springer, Cham; 2016. p. 271–305.
40. Martín-Martínez M, Pérez-Gordillo FL, Alvarez de la Rosa D, Rodríguez Y, Gerona-Navarro G, González-Muñiz R, Zhou M-M. Modulating Mineralocorticoid
Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects. J Med
Chem. 2017;60:2629–2650.
41. Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE. Non-steroidal mineralocorticoid receptor antagonism for the treatment of
cardiovascular and renal disease. Eur J Heart Fail. 2015;18:28–37.